For a patient requiring sliding‑scale insulin, what are the target glucose range and correction dose parameters, and which rapid‑acting insulin pen (e.g., insulin aspart [NovoLog], insulin lispro [Humalog], insulin glulisine [Apidra]) is recommended?

Sliding Scale Insulin Should Be Avoided—Use Scheduled Basal-Plus or Basal-Bolus Insulin Instead

Sliding scale insulin (SSI) alone is strongly discouraged for hospitalized patients with diabetes and should be replaced with scheduled insulin regimens that include basal insulin plus correction doses. 1, 2

Why Sliding Scale Insulin Fails

The evidence is clear and consistent: sliding scale insulin is a reactive, ineffective approach that treats hyperglycemia after it occurs rather than preventing it 2. Key problems include:

• Poor glycemic control: Only 6-12% of patients achieve target glucose levels with SSI alone 3
• Persistent hyperglycemia: Blood glucose remains elevated after 84% of SSI injections 3
• Increased complications: SSI is associated with higher rates of postoperative infections, pneumonia, bacteremia, and renal/respiratory failure compared to scheduled insulin 1
• Documentation failures: Approximately 30% of SSI administrations have missing or uncertain information about timing, dose, or glucose values 3

The Recommended Approach: Basal-Plus Regimen

For most hospitalized patients requiring insulin, use a basal-plus regimen consisting of:

Initial Dosing Parameters

Starting dose: 0.1–0.25 units/kg/day of basal insulin 1

• Use the lower end (0.1 units/kg) for:

  • Older patients (>65 years)
  • Renal insufficiency
  • Poor or uncertain oral intake
  • Mild hyperglycemia (glucose <200 mg/dL or <11.1 mmol/L)

• Use higher doses (0.3–0.5 units/kg/day total) only for:

  • Insulin-naive patients with consistent oral intake
  • Known diabetes on home insulin (but reduce home dose by 20% to prevent hypoglycemia) 1

Correction Insulin Parameters

Add rapid-acting insulin for correction doses:

• Check glucose before meals (if eating) or every 4-6 hours (if NPO) 2
• Use a correction scale based on insulin sensitivity:
  • Insulin-sensitive patients: 1 unit per 50 mg/dL above target
  • Average sensitivity: 1 unit per 40 mg/dL above target
  • Insulin-resistant patients: 1 unit per 30 mg/dL above target

Target glucose range: 100–180 mg/dL (5.6–10.0 mmol/L) for most hospitalized patients 1

Which Rapid-Acting Insulin Pen to Use

All three rapid-acting insulin analogs are clinically equivalent—choose based on formulary availability and cost. 4, 5

The available options are:

• Insulin lispro (Humalog) 6
• Insulin aspart (NovoLog)
• Insulin glulisine (Apidra)

These insulins have:

• Onset: 15 minutes
• Peak: 30–90 minutes 6
• Duration: 3–5 hours
• Equivalent potency: 1 unit of any rapid-acting analog = 1 unit of regular human insulin 6

Real-world registry data from 42,736 patients showed no clinically meaningful differences in HbA1c, fasting glucose, or hypoglycemia rates between glulisine versus lispro/aspart 4. All three are preferred over regular human insulin due to faster onset and shorter duration, which better matches physiologic meal-related insulin secretion 5.

Critical Pitfalls to Avoid

1. Never use SSI alone in patients with type 1 diabetes—they require basal insulin to prevent diabetic ketoacidosis 1

2. Avoid the basal-bolus regimen initially unless the patient has:

   • Consistent meal intake
   • Glucose consistently >200 mg/dL
   • Known high insulin requirements at home

   The basal-bolus approach carries a 4–6 times higher risk of hypoglycemia than basal-plus regimens 1

3. Do not use premixed insulins (70/30) in the hospital—they cause unacceptably high rates of hypoglycemia 1

4. Adjust the regimen daily based on glucose patterns—the most common error with SSI was failure to adjust therapy despite persistent hyperglycemia 3

When SSI Alone Might Be Acceptable

The only appropriate use of sliding scale insulin alone is in patients without pre-existing diabetes who develop mild stress hyperglycemia (glucose <200 mg/dL) 1. Even then, basal-plus is safer and more effective.

Algorithm Summary

1. Start basal insulin: 0.1–0.25 units/kg/day (use long-acting analog like glargine or detemir)
2. Add correction insulin: Rapid-acting analog (lispro, aspart, or glulisine) before meals or every 4-6 hours if NPO
3. Use correction scale: Based on insulin sensitivity (typically 1 unit per 40 mg/dL above 140 mg/dL target)
4. Monitor and adjust daily: Increase basal by 10-20% if fasting glucose remains >140 mg/dL
5. Transition to basal-bolus only if glucose remains >200 mg/dL despite basal-plus optimization

This approach reduces complications, improves glycemic control, and maintains patient safety compared to the outdated sliding scale insulin monotherapy 1, 2.